Bayer BAYRY announced that the FDA has accepted its new drug application (NDA) for its investigational, once-daily, oral ...

A major international trial suggests an experimental anti-clotting drug may lower the risk of repeat strokes without the ...

Asundexian plus antiplatelet therapy reduces IS risk in patients with noncardioembolic stroke or high-risk transient ischemic attack.

A stroke can happen suddenly and without warning, but health experts say the body often sends critical signals that should ...

Strokes can happen in an instant and knowing the warning signs could save a life. Moayad Ismail, MD, Adult Medicine Physician ...

All the wonderful and most welcome signs of the new life surround us. (Sorry, allergy sufferers! I do feel your pain!)  The ...

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes ...

The FDA granted Priority Review to the novel Factor XIa inhibitor asundexian for secondary stroke prevention following an ischemic stroke.